• 1
    Seeff LB. Natural history of chronic hepatitis C. HEPATOLOGY 2002; 36: S35-S46.
  • 2
    Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008; 134: 1699-714.
  • 3
    Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Mullhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 655-666.
  • 4
    De Nicola S, Aghemo A, Rumi MG, Colombo M. HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 964-966.
  • 5
    Marcolongo M, Young B, Dal Pero F, Fattovich G, Peraro L, Guido M, et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. HEPATOLOGY 2009; 50: 1038-1044.
  • 6
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
  • 7
    Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
  • 8
    Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
  • 9
    Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345, 1345e1-e7.
  • 10
    Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461: 798-801.
  • 11
    Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR, Goldstein DB. Hepatitis C pharmacogenetics: State of the art in 2010. HEPATOLOGY 2011; 53: 336-345.
  • 12
    R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2009. Available at:
  • 13
    Terry Therneau and original R port by Thomas Lumley. Survival: survival analysis, including penalised likelihood. R package version 2.35–7. 2009. Available at: Accessed on February 18, 2011.
  • 14
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832.
  • 15
    Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-739.
  • 16
    Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C, et al., HENCORE collaboration. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003; 52: 574-579.
  • 17
    Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. HEPATOLOGY 2010; 51: 1904-1911.
  • 18
    IL28B genetic polymorphism has genome wide significant associations with serum low density lipoprotein levels and hepatic steatosis in patients with genotype 1 chronic hepatitis C. HEPATOLOGY 2010; 52( Suppl 1): 439A.
  • 19
    Stättermayer A, Rutter K, Beinhardt S, Scherzer TM, Zinober K, Hofer H, et al. Influence of IL28B-genotype on insulin resistance in treatment-naïve patients with chronic hepatitis C [Abstract]. HEPATOLOGY 2010; 52( Suppl 1): 1224A.
  • 20
    Bitetto D, Fabris C, Fornasiere E, Fumolo E, Cussigh A, Bignulin S, et al. IL28B rs12979860 C>T polymorphism affects the evolution of chronic hepatitis C [Abstract]. HEPATOLOGY 2010; 52( Suppl 1): 438A.
  • 21
    Del Campo JA, Maraver Zamora M, Ramírez-Lorca R, Pardo-Yules B, Sáez ME, Real LM. IL28B polymorphism predicts sustained virological response in hepatitis C but is not associated with fibrosis or viral load [Abstract]. HEPATOLOGY 2010; 52( Suppl 1): 748A.
  • 22
    Thompson AJ, Clark PJ, Fellay J, Muir AJ, Tillmann HL, Patel K, et al. IL28B genotype is not associated with advanced hepatic fibrosis in chronic hepatitis C patients enrolled in the ideal study [Abstract]. HEPATOLOGY 2010; 52( Suppl 1): 437A.
  • 23
    Thompson AJ, Clark PJ, Zhu M, Zhu Q, Ge D, Sulkowski MS, et al. Genome-wide association study identifies IL28B polymorphism to be associated with baseline alt and hepatic necro-inflammatory activity in chronic hepatitis C patients enrolled in the IDEAL study [Abstract]. HEPATOLOGY 2010; 52( Suppl 1): 1220A.
  • 24
    Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104.
  • 25
    Casiraghi MA, De Paschale M, Romanò L, Biffi R, Assi A, Binelli G, Zanetti AR. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. HEPATOLOGY 2004; 39: 90-96.
  • 26
    Tovo PA, Pembrey LJ, Newell ML. Persistence rate and progression of vertically acquired hepatitis C infection. European Paediatric Hepatitis C Virus Infection. J Infect Dis 2000; 181: 419-424.
  • 27
    Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male P-J, Giostra E, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004; 53: 406-412.
  • 28
    Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-1642.
  • 29
    Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. HEPATOLOGY 2005; 41: 82-87.
  • 30
    Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterology 2002; 97: 2614-2618.
    Direct Link:
  • 31
    Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008; 134: 1670-1681.
  • 32
    Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009; 50: 1-3.